Centessa
1 known investors
Centessa Pharmaceuticals is developing an Orexin Receptor 2 Agonist program to treat sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. The company aims to create transformational medicines for patients with these conditions.
BiotechHealthtech
Investors · 1
In the news
- Farallon reports 6.1% stake in Centessa | CNTA SEC Filing - Form SCHEDULE 13Dstocktitan.net · 2026
- Form SCHEDULE 13D Centessa Pharmaceuticals Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.streetinsider.com · 2026
- Why Centessa Pharmaceuticals (CNTA) Raised $250 Million and What It Means for Its R&D Ambitionsfinance.yahoo.com · 2025